Becton, Dickinson and Company (BD): BD is a premier global enterprise founded in 1897 in Franklin Lakes, New Jersey, United States. Operating under CEO Tom Polen, the company reported $19.37 billion in consolidated revenue and $1.77 billion in net income, managing over $38 billion in total assets. BD holds an essential hospital consumables monopoly, supplying billions of hypodermic needles, syringes, Vacutainer blood collection tubes, Alaris infusion pumps, and Pyxis dispensing stations to over 90% of global hospitals.
BD: Company Timeline
Maxwell W. Becton and Fairleigh S. Dickinson partner in New York City to form Becton, Dickinson and Company, initially distributing fever thermometers and hypodermic syringes. [source]
Becton, Dickinson and Company is officially incorporated in New Jersey and establishes its first dedicated manufacturing and assembly operations. [source]
BD introduces the groundbreaking Luer-Lok syringe tip, establishing an industry-standard secure connection for hypodermic needles and preventing accidental needle detachment. [source]
BD invents and launches the revolutionary Vacutainer evacuated blood collection tube system, transforming clinical diagnostics and laboratory blood draws worldwide. [source]
BD common stock is listed on the New York Stock Exchange under ticker symbol BDX, providing broad public liquidity and capital for international expansion. [source]
BD scales its global footprint across Europe and Asia, establishing state-of-the-art manufacturing plants for disposable medical consumables and diagnostic reagents. [source]
BD pioneers advanced fluorescence-activated cell sorting (FACS) and flow cytometry instrumentation, accelerating immunology and oncology research. [source]
In response to needlestick injuries and bloodborne pathogen transmission risks, BD introduces an extensive portfolio of safety-engineered needles and retractable syringes. [source]
BD completes the massive $12.2 billion acquisition of CareFusion, integrating Pyxis automated dispensing systems and Alaris infusion pump technologies. [source]
BD acquires C.R. Bard for $24 billion, dramatically expanding its Interventional segment into vascular, urology, oncology, and surgical specialty products. [source]
BD successfully completes the tax-free spin-off of its diabetes care business into an independent publicly traded company named Embecta Corp. [source]
BD completes the strategic $4.2 billion acquisition of Edwards Lifesciences Critical Care product group, boosting advanced hemodynamic monitoring capabilities. [source]
BD accelerates deployment of AI-enabled smart connected medication management systems, smart infusion pumps, and non-invasive PureWick urine management solutions. [source]
BD achieves record consolidated revenue of $19.37 billion, reinforcing its essential hospital consumable monopoly across 190+ countries. [source]
What Is the History of BD?
Founded in 1897 by Maxwell W. Becton and Fairleigh S. Dickinson, Becton Dickinson began as a distributor of fever thermometers and hypodermic syringes. Over more than a century of relentless innovation, BD introduced the Luer-Lok syringe tip in 1924 and the revolutionary Vacutainer blood collection tube in 1949, transforming clinical diagnostics. Through strategic multi-billion dollar acquisitions—including CareFusion in 2015 ($12.2B), C.R. Bard in 2017 ($24B), and Edwards Lifesciences Critical Care in 2024 ($4.2B)—BD evolved from a consumable needle manufacturer into a diversified healthcare technology titan.BD: Expert Analysis
Strategic Insight: Market Positioning & Economic Moat
BD’s enduring economic moat rests on an entrenched hospital consumables monopoly. Because clinical workflows in virtually every hospital worldwide rely on BD’s daily-use consumables (Vacutainer tubes, hypodermic needles, catheters), BD enjoys immense customer switching costs and trusted relationships that enable it to successfully cross-sell high-margin hospital automation systems like Pyxis and Alaris.BD: Founders
Maxwell W. Becton
Co-Founder & Pioneer
Maxwell W. Becton was a visionary commercial traveler and salesman who partnered with Fairleigh S. Dickinson in 1897 to sell thermometers and hypodermic needles to physicians and hospitals across the United States, establishing BD as a foundational medical supply enterprise.
Fairleigh S. Dickinson
Co-Founder & Inventor
Fairleigh S. Dickinson was an enterprising inventor and businessman who recognized the critical need for standardized, high-quality clinical instruments in healthcare, helping build BD into an indispensable global medical technology institution.
How Does BD Make Money?
BD generates revenue across diversified commercial and operating segments:
1. Medical Segment Consumables & Devices: Consists of medication delivery solutions, hypodermic needles, syringes, vascular access devices, and pharmaceutical systems supplied to hospitals worldwide.
2. Interventional Segment Products: Encompasses advanced surgery, peripheral vascular intervention, urology, oncology, and critical care monitoring systems gained through Bard and Edwards acquisitions.
3. Life Sciences & Diagnostics: Includes Vacutainer blood collection tubes, flow cytometry instruments, microbiology diagnostic systems, and molecular testing assays for clinical laboratories.
What Is BD's Competitive Advantage?
BD maintains critical economic advantages in its global industry:
Essential Consumables Monopoly: Billions of daily-use consumables create unassailable hospital relationships and sticky workflows.
Global Distribution Scale: Direct sales and distribution infrastructure spanning 190+ countries with deep regulatory compliance.
Smart Connected Ecosystems: Seamless integration between Pyxis dispensing cabinets, Alaris infusion pumps, and electronic health records.
Proprietary IP & R&D Leadership: Decades of patented medical innovations in biosciences, specimen collection, and interventional surgery.
Who Are BD's Main Competitors?
BD competes against major industry peers across key business sectors:
Baxter International: Major competitor in intravenous infusion therapies, renal care, and hospital medication delivery systems.
ICU Medical: Competes in infusion therapy, critical care, and IV systems following major portfolio expansions.
Abbott Laboratories: Global healthcare leader competing in rapid diagnostics, point-of-care testing, and medical devices.
Boston Scientific: Major rival in interventional medical devices, cardiology, and peripheral vascular technologies.
What Companies Has BD Acquired?
| Year | Company | Value | Strategic Purpose | Outcome |
|---|---|---|---|---|
| 2015 | CareFusion | $12.2 Billion | Added Pyxis automated medication dispensing systems and Alaris infusion pump platforms to establish medication management leadership. | Fully integrated into BD Medication Management Solutions. |
| 2017 | C.R. Bard | $24.0 Billion | Expanded BD into vascular, urology, oncology, and surgical specialty products, forming the robust Interventional segment. | Highly accretive segment driving advanced interventional growth. |
| 2024 | Edwards Lifesciences Critical Care | $4.2 Billion | Acquired advanced AI-powered hemodynamic monitoring and smart catheter technologies for intensive care units. | Integrated into BD Interventional / Advanced Monitoring. |
| 2021 | Vyaire Medical (Respiratory assets) | Undisclosed | Enhanced respiratory diagnostic and ventilation product capabilities during global healthcare demand spikes. | Successfully integrated. |
Who Leads BD?
Tom Polen
Chairman, Chief Executive Officer and President
Tom Polen has served as CEO of Becton Dickinson since January 2020, leading the company through major strategic acquisitions, digital transformation, and Alaris infusion pump portfolio revitalization.
Christopher R. Reidy
Executive Vice President, Chief Financial Officer and Chief Administrative Officer
Christopher R. Reidy directs global financial strategy, capital allocation, investor relations, and administrative operations for Becton Dickinson.
Dr. Elizabeth Ng
Executive Vice President and President of Medical Segment
Dr. Elizabeth Ng oversees BD’s massive worldwide Medical segment, encompassing medication delivery solutions, pharmaceutical systems, and vascular access technologies.
Michael David
Executive Vice President and President of Life Sciences Segment
Michael David manages the Life Sciences segment, driving global innovation in diagnostic systems, specimen management, and biosciences research.
Alberto Mas
Executive Vice President and President of Interventional Segment
Alberto Mas leads the Interventional segment, encompassing surgery, peripheral intervention, and urology care products resulting from major strategic acquisitions.
How Is BD Growing?
Under executive leadership, BD is executing several multi-year growth vectors:
1. Smart Connected Medication Management: Accelerating deployment of next-gen Alaris pumps and cloud-connected Pyxis dispensing automation.
2. Interventional & Advanced Monitoring Expansion: Scaling newly acquired Edwards Critical Care hemodynamic monitoring and Bard interventional portfolios.
3. Non-Invasive Care Innovation: Expanding PureWick and home-care medical device adoption to capture aging-in-place healthcare demand.
4. Emerging Markets Penetration: Expanding direct commercial footprint across high-growth healthcare markets in Asia-Pacific and Latin America.
What Are the Biggest Risks Facing BD?
BD navigates industry, macroeconomic, and competitive headwinds:
Regulatory & Compliance Scrutiny: Strict FDA oversight of medical device manufacturing, infusion pump software, and quality remediation.
Product Liability Litigation: Ongoing legal defense costs related to legacy interventional mesh and catheter products.
Hospital Budget Pressures: Macroeconomic headwinds, hospital staffing shortages, and capital expenditure tightening impacting device procurement.
Global Supply Chain Volatility: Vulnerability to raw material cost inflation, shipping disruptions, and component shortages.
BD: Quick Reference Q&A
Q: What is Becton Dickinson known for?
A: Becton Dickinson (BD) is globally renowned as an essential hospital consumables and medical technology monopoly, manufacturing billions of hypodermic needles, syringes, Vacutainer blood collection tubes, Alaris infusion pumps, and Pyxis medication dispensing stations.
Q: When was Becton Dickinson founded and who are its founders?
A: BD was founded in 1897 in Franklin Lakes, New Jersey (originally in New York) by Maxwell W. Becton and Fairleigh S. Dickinson, who partnered to distribute high-quality thermometers and hypodermic instruments.
Q: What is Becton Dickinson's stock symbol and where is it traded?
A: Becton Dickinson trades on the New York Stock Exchange under the ticker symbol BDX and is a prominent constituent of the S&P 500 index with a market capitalization exceeding $70 billion.
Q: How much annual revenue does Becton Dickinson generate?
A: In its most recent fiscal year, Becton Dickinson reported consolidated annual net revenue of $19.37 billion, supported by robust operating margins and diversified revenue streams across medical, interventional, and life sciences segments.
Q: Who is the current CEO of Becton Dickinson?
A: Tom Polen serves as the Chairman, Chief Executive Officer, and President of Becton Dickinson, having led the enterprise since January 2020 through major acquisitions and digital healthcare transformations.
Q: What are Becton Dickinson's core business segments?
A: BD operates across three primary business segments: BD Medical (medication delivery and pharmaceutical systems), BD Interventional (surgery, vascular, urology, and critical care), and BD Life Sciences (diagnostics and biosciences).
Q: What major acquisitions have shaped Becton Dickinson?
A: BD's growth has been supercharged by transformative acquisitions, most notably CareFusion for $12.2 billion in 2015, C.R. Bard for $24 billion in 2017, and the Edwards Lifesciences Critical Care unit for $4.2 billion in 2024.
Q: How many employees does Becton Dickinson have worldwide?
A: Becton Dickinson employs approximately 73,000 dedicated associates globally, operating manufacturing plants, R&D centers, and sales offices across more than 190 countries.
Q: What is the BD Alaris system?
A: The BD Alaris infusion system is a leading smart infusion pump platform equipped with Guardrails safety software that helps clinicians prevent medication administration errors in critical care hospital environments.
Q: What is the PureWick system manufactured by BD?
A: PureWick is BD's innovative non-invasive urine management system designed for female patients, providing an effective alternative to indwelling catheters and reducing the risk of urinary tract infections.
